10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A

Journal of Medicinal Chemistry

Volumn 58, Issue 7, 2015, Pages 3131-3143

  Falke, Hannes ^a   Chaikuad, Apirat ^b   Becker, Anja ^a   Loaëc, Nadège ^c,d   Lozach, Olivier ^d   Abu Jhaisha, Samira ^e   Becker, Walter ^e   Jones, Peter G ^a   Preu, Lutz ^a   Baumann, Knut ^a   Knapp, Stefan ^b   Meijer, Laurent ^c   Kunick, Conrad ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Centre de Perharidy   (France)

^d STATION BIOLOGIQUE   (France)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

10 IODO 11H INDOLO[3,2 C]QUINOLINE 6 CARBOXYLIC ACID; 10 IODO 3 METHOXY 11H INDOLO[3,2 C]QUINOLINE 6 CARBOXYLIC ACID; 11 IODO 3 METHOXY 7,12 DIHYDROINDOLO[3,2 D][1]BENZAZEPIN 6(5H) ONE; 11 IODO 7,12 DIHYDROINDOLO[3,2 D][1]BENZAZEPIN 6(5H) ONE; CARBOXYLIC ACID DERIVATIVE; ETHYL 10 IODO 3 METHOXY 11H INDOLO[3,2 C]QUINOLINE 6 CARBOXYLATE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; CARBOXYLIC ACID; DYRK KINASE; INDOLE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; QUINOLONE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC50; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; PROTEIN CONFORMATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CARBOXYLIC ACIDS; CHEMISTRY TECHNIQUES, SYNTHETIC; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; INDOLES; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84927593444     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501994d     Document Type: Article

References (80)

1. Lejeune, J.; Gautier, M.; Turpin, R. Study of somatic chromosomes from 9 mongoloid children C. R. Hebd. Seances Acad. Sci. 1959, 248, 1721-1722
2. Rachidi, M.; Lopes, C. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways Eur. J. Paediatr. Neurol. 2008, 12, 168-182
3. Korenberg, J. R.; Kawashima, H.; Pulst, S. M.; Ikeuchi, T.; Ogasawara, N.; Yamamoto, K.; Schonberg, S. A.; West, R.; Allen, L.; Magenis, E.; lkawa, K.; Taniguchi, N.; Epstein, C. J. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype Am. J. Hum. Genet. 1990, 47, 236-246
4. McCormick, M. K.; Schinzel, A.; Petersen, M. B.; Stetten, G.; Driscoll, D. J.; Cantu, E. S.; Tranebjaerg, L.; Mikkelsen, M.; Watkins, P. C.; Antonarakis, S. E. Molecular genetic approach to the characterization of the "Down syndrome region" of chromosome 21 Genomics 1989, 5, 325-331
5. Rahmani, Z.; Bloui, J. L.; Creau-Goldberg, N.; Watkins, P. C.; Mattei, J. F.; Poissonnier, M.; Prieur, M.; Chettouh, Z.; Nicole, A.; Aurias, A.; Sinet, P.-M.; Delabar, J.-M. Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 5958-5962
6. Park, J.; Song, W.; Chung, K. Function and regulation of Dyrk1A: towards understanding Down syndrome Cell. Mol. Life Sci. 2009, 66, 3235-3240
7. Tejedor, F. J.; Hämmerle, B. MNB/DYRK1A as a multiple regulator of neuronal development FEBS J. 2011, 278, 223-235
8. Wegiel, J.; Gong, C. X.; Hwang, Y. W. The role of DYRK1A in neurodegenerative diseases FEBS J. 2011, 278, 236-245
9. Savage, M. J.; Gingrich, D. E. Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease Drug Dev. Res. 2009, 70, 125-144
10. Kimura, R.; Kamino, K.; Yamamoto, M.; Nuripa, A.; Kida, T.; Kazui, H.; Hashimoto, R.; Tanaka, T.; Kudo, T.; Yamagata, H.; Tabara, Y.; Miki, T.; Akatsu, H.; Kosaka, K.; Funakoshi, E.; Nishitomi, K.; Sakaguchi, G.; Kato, A.; Hattori, H.; Uema, T.; Takeda, M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease Hum. Mol. Genet. 2007, 16, 15-23
11. Ryoo, S. R.; Jeong, H. K.; Radnaabazar, C.; Yoo, J. J.; Cho, H. J.; Le, H. W.; Kim, I. S.; Cheon, Y. H.; Ahn, Y. S.; Chung, S. H.; Song, W. J. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease J. Biol. Chem. 2007, 282, 34850-34857
12. Shi, J.; Zhang, T.; Zhou, C.; Choha, M. O.; Gu, X.; Wegiel, J.; Zhou, J.; Hwang, Y. W.; Iqbal, K.; Grundke-Iqbal, I.; Gong, C. X.; Liu, F. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome J. Biol. Chem. 2008, 283, 28660-28669
13. Toiber, D.; Azkona, G.; Ben-Ari, S.; Torán, N.; Soreq, H.; Dierssen, M. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations Neurobiol. Dis. 2010, 40, 348-359
14. Ryoo, S. R.; Cho, H. J.; Lee, H. W.; Jeong, H. K.; Radnaabazar, C.; Kim, Y. S.; Kim, M. J.; Son, M. Y.; Seo, H.; Chung, S. H.; Song, W. J. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease J. Neurochem. 2008, 104, 1333-1344
15. Ryu, Y. S.; Park, S. Y.; Jung, M. S.; Yoon, S. H.; Kwen, M. Y.; Lee, S. Y.; Choi, S. H.; Radnaabazar, C.; Kim, M. K.; Kim, H.; Kim, K.; Song, W. J.; Chung, S. H. Dyrk1A-mediated phosphorylation of presenilin 1: a functional link between Down syndrome and Alzheimer's disease J. Neurochem. 2010, 115, 574-584
16. Becker, W.; Joost, H. G. Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity Prog. Nucleic Acid Res. Mol. Biol. 1999, 62, 1-17
17. Himpel, S.; Panzer, P.; Eirmbter, K.; Czajkowska, H.; Sayed, M.; Packman, L. C.; Blundell, T.; Kentrup, H.; Grötzinger, J.; Joost, H. G.; Becker, W. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A Biochem. J. 2001, 359, 497-505
18. Kentrup, H.; Becker, W.; Heukelbach, J.; Wilmes, A.; Schürmann, A.; Huppertz, C.; Kainulainen, H.; Joost, H. G. Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII J. Biol. Chem. 1996, 271, 3488-3495
19. Becker, W.; Sippl, W. Activation, regulation, and inhibition of DYRK1A FEBS J. 2011, 278, 246-256
20. Becker, W.; Soppa, U.; Tejedor, F. J. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies CNS Neurol. Disord.: Drug Targets 2014, 13, 26-33
21. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
22. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051
23. Hanks, S. K.; Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification FASEB J. 1995, 9, 576-596
24. Smith, B.; Medda, F.; Gokhale, V.; Dunckley, T.; Hulme, C. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem. Neurosci. 2012, 3, 857-872
25. Airaksinen, M. M.; Lecklin, A.; Saano, V.; Tuomisto, L.; Gynther, J. Tremorigenic effect and inhibition of tryptamine and serotonin receptor binding by beta-carbolines Pharmacol. Toxicol. 1987, 60, 5-8
26. Kim, H.; Sablin, S. O.; Ramsay, R. R. Inhibition of monoamine oxidase A by beta-carboline derivatives Arch. Biochem. Biophys. 1997, 337, 137-142
27. Ogawa, Y.; Nonaka, Y.; Goto, T.; Ohnishi, E.; Hiramatsu, T.; Kii, I.; Yoshida, M.; Ikura, T.; Onogi, H.; Shibuya, H.; Hosoya, T.; Ito, N.; Hagiwara, M. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A Nat. Commun. 2010, 1, 86
28. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update Biochem. J. 2003, 371, 199-204
29. Adayev, T.; Chen-Hwang, M. C.; Murakami, N.; Wegiel, J.; Hwang, Y. W. Kinetic properties of a MNB/DYRK1A mutant suitable for the elucidation of biochemical pathways Biochemistry 2006, 45, 12011-12019
30. Khan, N.; Afaq, F.; Saleem, M.; Ahmad, N.; Mukhtar, H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate Cancer Res. 2006, 66, 2500-2505
31. Debdab, M.; Carreaux, F.; Renault, S.; Soundararajan, M.; Fedorov, O.; Filippakopoulos, P.; Lozach, O.; Babault, L.; Tahtouh, T.; Baratte, B.; Ogawa, Y.; Hagiwara, M.; Eisenreich, A.; Rauch, U.; Knapp, S.; Meijer, L.; Bazureau, J. P. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing J. Med. Chem. 2011, 54, 4172-4186
32. Fant, X.; Durieu, E.; Chicanne, G.; Payrastre, B.; Sbrissa, D.; Shisheva, A.; Limanton, E.; Carreaux, F.; Bazureau, J. P.; Meijer, L. Cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease Mol. Pharmacol. 2014, 85, 441-450
33. Tahtouh, T.; Elkins, J. M.; Filippakopoulos, P.; Soundararajan, M.; Burgy, G.; Durieu, E.; Cochet, C.; Schmid, R. S.; Lo, D. C.; Delhommel, F.; Oberholzer, A. E.; Pearl, L. H.; Carreaux, F.; Bazureau, J. P.; Knapp, S.; Meijer, L. Selectivity, cocrystal structures and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B J. Med. Chem. 2012, 55, 9312-9330
34. Giraud, F.; Alves, G.; Debiton, E.; Nauton, L.; Théry, V.; Durieu, E.; Ferandin, Y.; Lozach, O.; Meijer, L.; Anizon, F.; Pereira, E.; Moreau, P. Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives J. Med. Chem. 2011, 54, 4474-4489
35. Myrianthopoulos, V.; Kritsanida, M.; Gaboriaud-Kolar, N.; Magiatis, P.; Ferandin, Y.; Durieu, E.; Lozach, O.; Cappel, D.; Soundararajan, M.; Filippakopoulos, P.; Sherman, W.; Knapp, S.; Meijer, L.; Mikros, E.; Skaltsounis, A. L. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases ACS Med. Chem. Lett. 2013, 4, 22-26
36. Leblond, B.; Casagrande, A.-S.; Désiré, L.; Foucourt, A.; Besson, T. Tricyclic pyrimidines as inhibitors of DYRK1A/DYRK1B as potential treatment for Down's syndrome or Alzheimer's disease. WO 2013/026806A1, 2013.
37. Anderson, K.; Chen, Y.; Chen, Z.; Dominique, R.; Glenn, K.; He, Y.; Janson, C.; Luk, K. C.; Lukacs, C.; Polonskaia, A.; Qiao, Q.; Railkar, A.; Rossman, P.; Sun, H.; Xiang, Q.; Vilenchik, M.; Wovkulich, P.; Zhang, X. Pyrido[2,3- d ]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 6610-6615
38. Gourdain, S.; Dairou, J.; Denhez, C.; Bui, L. C.; Rodrigues-Lima, F.; Janel, N.; Delabar, J. M.; Cariou, K.; Dodd, R. H. Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity J. Med. Chem. 2013, 56, 9569-9585
39. Fedorov, O.; Huber, K.; Eisenreich, A.; Filippakopoulos, P.; King, O.; Bullock, A. N.; Szklarczyk, D.; Jensen, L. J.; Fabbro, D.; Trappe, J.; Rauch, U.; Bracher, F.; Knapp, S. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing Chem. Biol. 2011, 18, 67-76
40. Schmitt, C.; Kail, D.; Mariano, M.; Empting, M.; Weber, N.; Paul, T.; Hartmann, R. W.; Engel, M. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors PLoS One 2014, 9, e87851
41. Schmitt, C.; Miralinaghi, P.; Mariano, M.; Hartmann, R. W.; Engel, M. Hydroxybenzothiophene ketones are efficient pre-mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1/4 ACS Med. Chem. Lett. 2014, 5, 963-967
42. Becker, A.; Kohfeld, S.; Lader, A.; Preu, L.; Pies, T.; Wieking, K.; Ferandin, Y.; Knockaert, M.; Meijer, L.; Kunick, C. Development of 5-benzylpaullones and paullone-9-carboxylic acid alkyl esters as selective inhibitors of mitochondrial malate dehydrogenase (mMDH) Eur. J. Med. Chem. 2010, 45, 335-342
43. Kunick, C.; Lauenroth, K.; Leost, M.; Meijer, L.; Lemcke, T. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 Bioorg. Med. Chem. Lett. 2004, 14, 413-416
44. Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jorgensen, F. S.; Lemcke, T. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones J. Med. Chem. 2004, 47, 22-36
45. Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Leost, M.; Meijer, L. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity Bioorg. Med. Chem. Lett. 2000, 10, 567-569
46. Kunick, C.; Zeng, Z.; Gussio, R.; Zaharevitz, D.; Leost, M.; Totzke, F.; Schächtele, C.; Kubbutat, M. H. G.; Meijer, L.; Lemcke, T. Structure-aided optimization of kinase inhibitors derived from alsterpaullone ChemBioChem 2005, 6, 541-549
47. Lahusen, T.; De Siervi, A.; Kunick, C.; Senderowicz, A. M. Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase 9 due to perturbation in mitochondrial membrane potential Mol. Carcinog. 2003, 36, 183-194
48. Leost, M.; Schultz, C.; Link, A.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25 Eur. J. Biochem. 2000, 267, 5983-5994
49. Pies, T.; Schaper, K.-J.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Meijer, L.; Kunick, C. CDK1-inhibitory activity of paullones depends on electronic properties of 9-substituents Arch. Pharm. (Weinheim, Ger.) 2004, 337, 486-492
50. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/ cyclin B inhibition, and in vitro antitumor activity J. Med. Chem. 1999, 42, 2909-2919
51. Tolle, N.; Kunick, C. Paullones as inhibitors of protein kinases Curr. Top. Med. Chem. 2011, 11, 1320-1332
52. Wieking, K.; Knockaert, M.; Leost, M.; Zaharevitz, D. W.; Meijer, L.; Kunick, C. Synthesis of paullones with aminoalkyl side chains Arch. Pharm. (Weinheim, Ger.) 2002, 335, 311-317
53. Zaharevitz, D. W.; Gussio, R.; Leost, M.; Senderowicz, A.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases Cancer Res. 1999, 59, 2566-2569
54. Becker, A.; Kohfeld, S.; Pies, T.; Wieking, K.; Preu, L.; Kunick, C. Synthesis of 11 H -indolo[3,2- c ]quinoline-6-carboxylic acids by cascade autoxidation-ring contractions Synthesis 2009, 1185-1189
55. Ryczak, J.; Papini, M.; Lader, A.; Nasereddin, A.; Kopelyanskiy, D.; Preu, L.; Jaffe, C. L.; Kunick, C. 2-Arylpaullones are selective antitrypanosomal agents Eur. J. Med. Chem. 2013, 64, 396-400
56. Maiwald, F.; Benítez, D.; Charquero, D.; Dar, M. A.; Erdmann, H.; Preu, L.; Koch, O.; Hölscher, C.; Loaëc, N.; Meijer, L.; Comini, M. A.; Kunick, C. 9- and 11-substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma Eur. J. Med. Chem. 2014, 83, 274-283
57. de Graaf, K.; Czajkowska, H.; Rottmann, S.; Packman, L. C.; Lilischkis, R.; Luscher, B.; Becker, W. The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site BMC Biochem. 2006, 7, 7
58. Göckler, N.; Jofre, G.; Papadopoulos, C.; Soppa, U.; Tejedor, F. J.; Becker, W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation FEBS J. 2009, 276, 6324-6337
59. Mariano, M.; Schmitt, C.; Miralinaghi, P.; Catto, M.; Hartmann, R. W.; Carotti, A.; Engel, M. First selective dual inhibitors of tau phosphorylation and beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease ACS Chem. Neurosci. 2014, 5, 1198-1202
60. Soundararajan, M.; Roos, A. K.; Savitsky, P.; Filippakopoulos, P.; Kettenbach, A. N.; Olsen, J. V.; Gerber, S. A.; Eswaran, J.; Knapp, S.; Elkins, J. M. Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition Structure 2013, 21, 986-996
61. Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology J. Med. Chem. 2013, 56, 1363-1388
62. Voth, A. R.; Ho, P. S. The role of halogen bonding in inhibitor recognition and binding by protein kinases Curr. Top. Med. Chem. 2007, 7, 1336-1348
63. Huber, K.; Brault, L.; Fedorov, O.; Gasser, C.; Filippakopoulos, P.; Bullock, A. N.; Fabbro, D.; Trappe, J.; Schwaller, J.; Knapp, S.; Bracher, F. 7,8-Dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes J. Med. Chem. 2012, 55, 403-413
64. Poznański, J.; Shugar, D. Halogen bonding at the ATP binding site of protein kinases: preferred geometry and topology of ligand binding Biochim. Biophys. Acta 2013, 1834, 1381-1386
65. Armarego, W. L. F.; Chai, C. L. L. Purification of Laboratory Chemicals; MPG Books: Bodmin, Cornwall, U.K., 2003.
66. Kunick, C. Synthese [ b ]-kondensierter azepindione durch dealkoxycarbonylierung Arch. Pharm. (Weinheim, Ger.) 1991, 324, 579-581
67. Egert-Schmidt, A.-M.; Dreher, J.; Dunkel, U.; Kohfeld, S.; Preu, L.; Weber, H.; Ehlert, J. E.; Mutschler, B.; Totzke, F.; Schächtele, C.; Kubbutat, M. H. G.; Baumann, K.; Kunick, C. Identification of 2-anilino-9-methoxy-5,7-dihydro-6 H -pyrimido[5,4- d ][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation J. Med. Chem. 2010, 53, 2433-2442
68. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y.-Z.; Mandelkow, E.-M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen kinase-3b and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease-a property common to most CDK inhibitors? J. Biol. Chem. 2001, 276, 251-260
69. Primot, A.; Baratte, B.; Gompel, M.; Borgne, A.; Liabeuf, S.; Romette, J. L.; Costantini, F.; Meijer, L. Purification of GSK-3 by affinity chromatography on immobilised axin Protein Expression Purif. 2000, 20, 394-404
70. Reinhardt, J.; Ferandin, Y.; Meijer, L. Purification of CK1 by affinity chromatography on immobilised axin Protein Expression Purif. 2007, 54, 101-109
71. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125-132
72. Battye, T. G.; Kontogiannis, L.; Johnson, O.; Powell, H. R.; Leslie, A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 271-281
73. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
74. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674
75. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501
76. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
77. Painter, J.; Merritt, E. A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 439-450
78. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B., 3rd; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 2007, 35, W375-W383
79. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
80. Molecular Operating Environment (MOE); Chemical Computing Group Inc. (1010 Sherbrooke St. W, Suite 910, Montreal, Quebec, Canada, H3A 2R7), 2014.